

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number  
**WO 2004/028529 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/202,**  
**A61P 25/28**

Mishima-gun, Osaka 618-0001 (JP). **KOGA, Yoshihiko**  
[JP/JP]; 2-4-5, Kaminoge, Setagaya-ku, Tokyo 158-0093  
(JP).

(21) International Application Number:  
**PCT/JP2003/012107**

(74) Agents: **AOKI, Atsushi et al.; A. AOKI, ISHIDA & AS-**  
**SOCIATES, Toranomon 37 Mori Bldg., 5-1, Toranomon**  
**3-chome, Minato-ku, Tokyo 105-8423 (JP).**

(22) International Filing Date:  
22 September 2003 (22.09.2003)

(25) Filing Language: English

(81) Designated States (*national*): AU, CA, CN, ID, IN, JP,  
KR, SG, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(30) Priority Data:  
NO. 2002-277305  
24 September 2002 (24.09.2002) JP

Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(71) Applicant (*for all designated States except US*): **SUN-**  
**TORY LIMITED [JP/JP]; 1-40, Dojimahama 2-chome,**  
**Kita-ku, Osaka-shi, Osaka 530-8203 (JP).**

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **AKIMOTO,**  
**Kengo [JP/JP]; 1-9-5-1006, Yamazaki, Shimamoto-cho,**

*For two-letter codes and other abbreviations, refer to the "Guid-*  
*ance Notes on Codes and Abbreviations" appearing at the begin-*  
*ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION WITH EFFECTS OF DECLINE PREVENTION, IMPROVEMENT OR ENHANCEMENT OF NORMAL RESPONSES OF COGNITIVE ABILITIES OF A HEALTHY PERSON

(57) Abstract: Arachidonic acid and/or compounds containing arachidonic acid as a constituent fatty acid are used to obtain compounds which prevent decline of, improve or enhance normal responses of cognitive abilities of a healthy person, and which are highly suitable for pharmaceuticals as well as food products, with minimal side effects.



**WO 2004/028529 A1**

## DESCRIPTION

COMPOSITION WITH EFFECTS OF DECLINE PREVENTION,  
IMPROVEMENT OR ENHANCEMENT OF NORMAL RESPONSES OF  
5 COGNITIVE ABILITIES OF A HEALTHY PERSON

## FIELD OF THE INVENTION

10 The present invention provides foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, containing, as active ingredients, arachidonic acid and/or compounds with arachidonic acid as a constituent fatty acid, and a process for their  
15 production. More specifically, the invention provides foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, awareness level and/or discriminatory ability with respect to events  
20 selected from the group consisting of auditory stimuli, visual stimuli, gustatory stimuli, olfactory stimuli and somatosensory stimuli, which contain, as active ingredients, one or more species selected from the group consisting of arachidonic acid, arachidonic acid alcohol  
25 esters and triglycerides, phospholipids or glycolipids containing arachidonic acid as part or all of the constituent fatty acid, as well as a process for their production.

## 30 BACKGROUND ART

Cognition is the process of selecting information from the external environment and clearly identifying it, and more specifically, of transmitting external stimuli such as visual, auditory, olfactory, gustatory and  
35 somatosensory stimuli to the brain through sensory organs and processing and precisely identifying them by coordinated functioning of multiple regions of the brain.

Cognitive abilities consist of the two factors of information processing speed (speed of transforming external stimuli) and the amount of information processing resources (the level of resource allocation for information processing on external stimuli), and the effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person according to the present invention are therefore understood to refer to decline prevention, improvement or enhancement of normal functions such as attention, memory, perception, language, calculation and the like, while being distinct from improvement of impaired function.

Various therapeutic agents have been researched and developed in relation to impaired cognitive function. Unfortunately, however, no effective compounds have yet been found that prevent decline of, improve or enhance normal responses of cognitive abilities of a healthy person. That is, although methods are known for determining cognitive function impairment and evaluating improving effects (see, for example, Nishimura, T., Takeda, M., "Diagnostic imaging of Alzheimer's dementia", pp.27-36, Medical View Publications (2/10/2001)) are known, such methods do not allow evaluation of decline prevention, improvement or enhancement of normal responses. A need has therefore existed for an effective means of objectively evaluating normal responses of cognitive abilities of a healthy person in order to objectively develop and research drug agents for decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person.

Attention has recently become focused on event related potentialss of brain as a physiological index to serve as an objective evaluation of cognitive ability. It is possible to record the electrical activity exhibited by neurons through electrodes attached on the human scalp. Background brain waves are generally known

as continuous electrical activity which varies depending on the arousal level. A transient minute action potential is also present which varies in relation to a given specifiable event. This action potential is currently referred to as the "event related potentialss of brain", and is interpreted as the potential induced by internal or external stimuli. The event related potentialss of brain, a minute potential variation of about 0.1  $\mu$ V to several tens of  $\mu$ V, is composed of a series of positive waves and negative waves. The positive wave appearing near 300 msec for the stimulus event among this series of potential variation is associated with cognitive function and is termed P300. The time to appearance of P300 for a stimulus event is called the P300 latency and represents information processing speed (speed of transforming external stimuli), while the height of the peak from the baseline is called the P300 amplitude and represents the amount of information processing resources (the level of resource allocation for information processing on external stimuli) (see, for example, Mitamura, S., "Current Therapy", Vol.18, No.4, pp.618-621, Life Medicom (2/10/2001)). It has thus become possible to objectively measure human cognitive response by measuring the event related potentialss of brain.

External stimuli are transmitted through sensory organs to the brain, and the brain is the tissue like adipose mass, about 1/3 of the white matter and 1/4 of the gray matter consists of phospholipids. Because most of the polyunsaturated fatty acids of the phospholipids constituting the cell membranes of the brain are arachidonic acid and docosahexaenoic acid, it has been suggested that these polyunsaturated fatty acids may play some role in enhancing learning and memory abilities and preventing or improving senile dementia. Arachidonic acid and docosahexaenoic acid cannot be synthesized *de novo* in animals and therefore must be ingested from food

either directly or indirectly (as linoleic acid precursor of arachidonic acid or  $\alpha$ -linoleic acid precursor of docosahexaenoic acid). Attention has thus been focused on enhancing effects on learning and memory and

5 preventive and improving effects on senile dementia by externally supplying arachidonic acid and docosahexaenoic acid. Docosahexaenoic acid is found abundantly in fish oil sources and a great deal of research has been conducted on its effects of brain function improvement,

10 while inventions have been disclosed in regard to its use in learning ability reinforcers, memory reinforcers, dementia preventing agents, dementia treatment agents, anti-dementia agents or functional foods with brain function-improving effects (see, for example, Japanese

15 Unexamined Patent Publication No. 7-82146, Japanese Unexamined Patent Publication No. 5-117147 and Japanese Unexamined Patent Publication No. 2-49723). Furthermore, arachidonic acid and/or compounds containing arachidonic acid as a constituent fatty acid have recently been shown

20 by the present inventors, to improve age-related decline in learning ability, based on results of administering arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid to aged animals subjected to a Morris water maze test, as described in

25 Japanese Unexamined Patent Publication No. 2003-48831, which was published on February 21, 2003, entitled "Composition Having Effects Of Preventing Or Ameliorating Conditions Or Diseases Caused By Brain Hypofunction". However, this particular invention is directed toward

30 decline in brain function and discloses nothing regarding effects on normal responses of cognitive abilities of a healthy person.

Some attempts have been made to determine the improving effects of several compounds on cognitive

35 response based on event related potentialss of brain. Miyanaga, K. examined the pharmacological action of DHA on brain function, measuring event related potentialsss

of brain before and after orally administering capsules containing 2400 mg DHA to 26 healthy subjects, and discovered that the P300 latency was significantly shortened and the P300 amplitude was significantly augmented (see Miyanaga, K., "Shoku no Kagaku" [Food Science] pp.84-96, Korin Books (1999)). However, due to a lack of comparative results with placebo samples, no correlation could be established between blood DHA levels and P300 results. In a prolonged administration test with daily administration of capsules containing 900 mg DHA to 97 healthy geriatric subjects for 6 months, no change in P300 was observed, thus leaving uncertainty about the efficacy of DHA.

Therefore, while docosahexaenoic acid is considered to exhibit an improving effect on learning ability, the fact that no effective results were found in terms of the event related potentials of brain as an index of cognitive ability means that it remains unclear whether or not arachidonic acid and/or compounds with arachidonic acid as a constituent fatty acid are effective for decline prevention, improvement and enhancement of normal responses of cognitive abilities of a healthy person.

#### DISCLOSURE OF THE INVENTION

##### Problems to be Solved by the Invention

Consequently, it has been ardently desired to develop compounds which prevent decline of, improve or enhance normal responses of information processing speed (speed of transforming external stimuli) and the amount of information processing resources (the level of resource allocation for information processing on external stimuli), as the two factors of cognitive abilities, and which are highly suitable for pharmaceuticals as well as food products, with minimal side effects.

##### Means for Solving the Problems

The present invention therefore provides foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, containing, as active ingredients, arachidonic acid and/or compounds with arachidonic acid as a constituent fatty acid, and a process for their production. More specifically, the invention provides foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, awareness level and/or discriminatory ability with respect to events (auditory stimuli, visual stimuli, gustatory stimuli, olfactory stimuli, somatosensory stimuli), which contains as active ingredients one or more species selected from the group consisting of arachidonic acid, arachidonic acid alcohol esters and triglycerides, phospholipids or glycolipids comprising arachidonic acid as part or all of the constituent fatty acid, as well as a process for their production.

As a result of diligent research for the purpose of elucidating the effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person by arachidonic acid and/or compounds comprising arachidonic acid as a constituent fatty acid, the present inventors surprisingly discovered an effect of arachidonic acid and/or compounds comprising arachidonic acid as a constituent fatty acid, based on evaluation using the event related potentials of brain as an index.

The present inventors also succeeded in achieving microbial industrial production of triglycerides containing at least 10 wt% arachidonic acid, and elucidated the effects of those triglycerides in effects tests according to the invention.

The present inventors further succeeded in achieving enzymatic production of oils and fats containing triglycerides with medium-chain fatty acids bound at the

1,3-positions and arachidonic acid bound at the 2-position, and elucidated the effects of those triglycerides in effects tests according to the invention.

5           The present invention therefore provides foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, containing as active ingredients arachidonic acid and/or compounds with arachidonic acid  
10 as a constituent fatty acid, and a process for their production. More specifically, the invention provides foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, awareness level  
15 and/or discriminatory ability with respect to events (auditory stimuli, visual stimuli, gustatory stimuli, olfactory stimuli, somatosensory stimuli), which contains as active ingredients one or more species selected from the group consisting of arachidonic acid, arachidonic acid alcohol esters and triglycerides,  
20 phospholipids or glycolipids comprising arachidonic acid as part or all of the constituent fatty acid, as well as a process for their production.

          According to the invention it is possible to provide  
25 foods and beverages having effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person which contains as active ingredients arachidonic acid and/or compounds with arachidonic acid as a constituent fatty acid, and a  
30 process for their production, thus the invention is particularly useful in modern society.

#### BRIEF DESCRIPTION OF THE DRAWINGS

          Fig. 1 is a bar graph showing changes in arachidonic  
35 acid levels in serum phospholipids before and after ingestion of arachidonic acid-containing edible oil capsules and olive oil-containing capsules (placebo



capsules).

Fig. 2 is a line graph showing changes in P300 latency before and after ingestion of arachidonic acid-containing edible oil capsules and olive oil-containing capsules (placebo capsules).

Fig. 3 is a line graph showing changes in P300 amplitude before and after ingestion of arachidonic acid-containing edible oil capsules and olive oil-containing capsules (placebo capsules).

Fig. 4 is a pair of dot graphs showing correlation between P300 (P300 latency and amplitude) and arachidonic acid levels in serum phospholipids.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to foods and beverages with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, comprising as active ingredients arachidonic acid and/or compounds with arachidonic acid as a constituent fatty acid, and to a process for their production.

The compositions of the invention have effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, or stated differently, they have effects of decline prevention, improvement or enhancement of normal responses of awareness level of a healthy person and have effects of decline prevention, improvement or enhancement of normal responses of discriminatory ability of a healthy person with respect to events (auditory stimuli, visual stimuli, gustatory stimuli, olfactory stimuli, somatosensory stimuli), and are able to exhibit their effects in foods or beverages, pharmaceuticals, quasi drugs and the like. The effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person are also effective as foods or beverages, pharmaceuticals and

quasi drugs designed for the purpose of decline prevention, improvement or enhancement of normal functions such as attention, memory, perception, language, calculation and the like, and as foods or beverages, healthy foods, functional foods, special health care foods, infant foods, geriatric foods, etc. designed for the purpose of maintaining or enhancing concentration, maintaining attention, clearing the head or stimulating the mind, rejuvenation and the like.

10       The active ingredients according to the invention may be, instead of free arachidonic acid, any compounds having arachidonic acid as a constituent fatty acid. Compounds having arachidonic acid as a constituent fatty acid include arachidonic acid salts such as calcium and sodium salts, or arachidonic acid alcohol esters such as arachidonic methyl ester, arachidonic acid ethyl ester and the like. Triglycerides, diglycerides, monoglycerides, phospholipids or glycolipids containing arachidonic acid as part or all of the constituent fatty acid may also be used.

20       For application to a food product, the arachidonic acid is preferably in the form of triglycerides or phospholipids, and especially triglycerides. While virtually no natural sources of arachidonic acid-containing triglycerides (or triglycerides including triglycerides with arachidonic acid as part or all of the constituent fatty acid) are known, the present inventors have succeeded in enabling industrial use of triglycerides containing arachidonic acid as a constituent fatty acid, and have been the first to elucidate the effect of the active ingredient of the invention in humans by prolonged administration to humans and analysis of event related potentials of brain allowing objective evaluation of cognitive abilities, and to demonstrate that it has an effect of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person.

According to the present invention, therefore, there may be used triglycerides which include triglycerides wherein part or all of the constituent fatty acids are arachidonic acid as the active ingredient of the invention (arachidonic acid-containing triglycerides). For application to food products, the arachidonic acid-containing triglycerides are preferably in the form oils or fats (triglycerides) wherein the proportion of arachidonic acid is at least 20 wt% (W/W), preferably at least 30 wt% and more preferably at least 40 wt% of the total fatty acids of the triglycerides. According to the invention, therefore, there may be used any arachidonic acid-containing oils or fats (triglycerides) obtained by culturing microbes capable of producing the same.

As examples of microbes capable of producing arachidonic acid-containing oils or fats (triglycerides) there may be mentioned microbes belonging to the genus *Mortierella*, *Conidiobolus*, *Pythium*, *Phytophthora*, *Penicillium*, *Cladosporium*, *Mucor*, *Fusarium*, *Aspergillus*, *Rhodotorula*, *Entomophthora*, *Echinosporangium* or *Saprolegnia*. As microbes belonging to the genus *Mortierella* subgenus *Mortierella* there may be mentioned *Mortierella elongata*, *Mortierella exigua*, *Mortierella hygrophila*, *Mortierella alpina*, and the like. Specifically, there may be mentioned strains such as *Mortierella elongata* IFO8570, *Mortierella exigua* IFO8571, *Mortierella hygrophila* IFO5941, *Mortierella alpina* IFO8568, ATCC16266, ATCC32221, ATCC42430, CBS219.35, CBS224.37, CBS250.53, CBS343.66, CBS527.72, CBS529.72, CBS608.70, CBS754.68, etc.

These strains are all available without restriction from the Institute for Fermentation, Osaka (IFO), the American Type Culture Collection (ATCC) and the Centraalbureau voor Schimmelcultures (CBS). In addition, there may be used strain *Mortierella elongata* SAM0219 (FERM P-8703) (FERM BP-1239) separated from soil by the research group of the present inventors.

For culturing of the strains used for the invention, the spores, hypha or cells of a seed culture solution obtained by preculturing are inoculated to liquid or solid medium for main culturing. In the case of a liquid medium, the carbon source used may be any commonly used one such as glucose, fructose, xylose, saccharose, maltose, solubilized starch, molasses, glycerol or mannitol, although there is no limitation to these. As nitrogen sources there may be used organic nitrogen sources, including natural nitrogen sources such as peptone, yeast extract, malt extract, meat extract, casamino acid, corn steep liquor, soybean protein, defatted soybean, cottonseed meal or the like, as well as urea, and inorganic nitrogen sources such as sodium nitrate, ammonium nitrate and ammonium sulfate. If necessary, trace nutrient sources including inorganic salts such as phosphoric acid salts, magnesium sulfate, iron sulfate and copper sulfate or vitamins may also be used. These medium components are not particularly restricted so long as they are at concentrations which do not inhibit growth of the microbes. In practice, the carbon source will generally be added in a total amount of 0.1-40 wt% (W/V) and preferably 1-25 wt% (W/V). The initial nitrogen source addition may be at 0.1-10 wt% (W/V) and preferably 0.1-6 wt% (W/V), with further addition of the nitrogen source during culturing if desired.

Oils or fats (triglycerides) containing at least 45 wt% (W/W) arachidonic acid may be prepared as the active ingredient for the invention by controlling the carbon source concentration in the medium. The culturing produces cells in the growth phase up to day 2-4 of culturing, and cells in the oil/fat accumulating phase after day 2-4 of culturing. The initial carbon source concentration is 1-8 wt% and preferably 1-4 wt%, and the carbon source is successively added only during the initial periods of the cell growth phase and oil/fat

accumulating phase, up to a total successive carbon source addition of 2-20 wt% and preferably 5-15 wt%. The successive addition of the carbon source during the initial periods of the cell growth phase and oil/fat  
5 accumulating phase is based on the initial nitrogen source concentration, for a carbon source concentration of zero in the medium from the 7th day of culturing, preferably from the 6th day of culturing and more preferably from the 4th day of culturing, to obtain oils  
10 or fats (triglycerides) comprising at least 45 wt% arachidonic acid, as an active ingredient according to the invention.

The culturing temperature for the arachidonic acid-producing microbe will differ depending on the microbe,  
15 but may be 5-40°C and preferably 20-30°C, or the cells may be cultured at 20-30°C for growth and the culturing continued at 5-20°C to produce unsaturated fatty acids. Such temperature management can also be used to increase the proportion of polyunsaturated fatty acids among the  
20 produced fatty acids. The pH of the medium may be 4-10 and preferably 5-9, and the culturing method may be submerged culturing, shake culturing, or stationary culturing. The culturing will usually be conducted for 2-30 days, preferably for 5-20 days and more preferably  
25 for 5-15 days.

As a means for increasing the proportion of arachidonic acid in the arachidonic acid-containing oils or fats (triglycerides) other than controlling the carbon source concentration in the medium, the arachidonic acid-  
30 containing oils or fats may be selectively hydrolyzed to obtain arachidonic acid-rich oils or fats. Lipases used for selective hydrolysis are not specific to triglyceride positions and, as the hydrolytic activity is lower in proportion to the number of double bonds, fatty acid  
35 ester bonds other than those of polyunsaturated fatty acids are hydrolyzed. Also, transesterification occurs between the produced PUFA triglycerides, resulting in

triglycerides with increased polyunsaturated fatty acids (see, for example, Enhancement of Arachidonic Acid: Selective Hydrolysis of a Single-Cell Oil from *Mortierella* with *Candida cylindracea* lipase", J. Am. Oil Chem. Soc., 72, pp.1323-1327, AOCS Press (1998)). Thus, arachidonic acid-rich oils or fats (triglycerides) obtained by selective hydrolysis of arachidonic acid-containing oils or fats may be used as active ingredients according to the invention. A higher proportion of arachidonic acid is preferred with respect to the total fatty acids in arachidonic acid-containing oils or fats (triglycerides) of the invention in order to minimize the effects of the other fatty acids, but there is no restriction to a high proportion and, in practice, the absolute amount of arachidonic acid can pose a problem for application to food products, although oils or fats (triglycerides) containing arachidonic acid at 10 wt% or more may be used in practice.

As triglycerides comprising arachidonic acid as part or all of the constituent fatty acid according to the invention there may be used triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position. There may also be used oils or fats (triglycerides) comprising at least 5 mole percent, preferably at least 10 mole percent, more preferably at least 20 mole percent and most preferably at least 30 mole percent of triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position. The medium-chain fatty acids bound at the 1,3-positions of the triglycerides may be selected from among fatty acids of 6 to 12 carbons. As examples of fatty acids of 6 to 12 carbons there may be mentioned caprylic acid and capric acid, with 1,3-capryloyl-2-arachidonoyl-glycerol (hereinafter referred to as "8A8") being preferred.

Triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-

position are most suitable as oils or fats (triglycerides) for infants or elderly persons. Ingested oils or fats (triglycerides) are usually hydrolyzed by pancreatic lipases upon entering the small intestine, and since pancreatic lipases are 1,3-position specific type, the 1,3-positions of the triglycerides are cleaved to produce two free fatty acid molecules while simultaneously producing one 2-monoacylglyceride (MG) molecule. Because 2-MG has very high bile acid solubility and is highly absorbable, 2-position fatty acids are generally considered to be better absorbed. Also, 2-MG exhibits surfactant action when dissolved in bile acids, and thus functions to increase the absorption of the free fatty acids. The free fatty acids and 2-MG then form bile acid complex micelles with cholesterol or phospholipids and are taken up by intestinal epithelial cells, resulting in resynthesis of triacylglycerols and finally release into the lymph as chylomicrons. However, the fatty acid properties of the pancreatic lipases are highest for saturated fatty acids, while arachidonic acid is cleaved less efficiently. An additional problem is that pancreatic lipase activity is lower in infants and the elderly, such that the ideal oils or fats (triglycerides) are triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position.

One specific production process for triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position is a production process whereby lipase is allowed to act only on 1,3-ester bonds of triglycerides in the presence of arachidonic- containing oils or fats (triglycerides) and medium-chain fatty acids.

The oil or fat (triglycerides) used as the starting material consists of triglycerides with arachidonic acid as a constituent fatty acid, and when the proportion of arachidonic acid is high with respect to the total fatty

acids of the triglycerides, a temperature of 30-50°C and preferably 40-50°C is employed which is higher than the ordinary enzyme reaction temperature of 20-30°C, in order to prevent reduction in reaction yield due to increase in unreacted oil or fat (the triglyceride starting material and the triglycerides wherein only one of the 1,3-position fatty acids is a medium-chain fatty acid).

As lipases which act specifically on the 1,3-position ester bonds of triglycerides there may be mentioned those produced by microbes belonging to the genus *Rhizopus*, *Rhizomucor*, *Aspergillus* or the like, as well as pig pancreatic lipases. Such lipases may be commercially available ones. Examples thereof include *Rhizopus delemar* lipase (Talipase, product of Tanabe Seiyaku), *Rhizomucor miehei* lipase (Ribozyme IM by Novo Nordisk Co., Ltd.) and *Aspergillus niger* lipase (Lipase A, product of Amano Enzyme Co., Ltd.), with no particular limitation to these enzymes, as any 1,3-position specific type lipases may be used.

The form in which the lipase is used is preferably as an immobilized lipase on an immobilizing support, in order to confer heat stability to the enzyme as the reaction temperature is 30°C or higher and preferably 40°C or higher for increased reaction efficiency. Highly porous resins are used as immobilizing supports, and there may be mentioned ion-exchange resin supports with pores of at least about 100 angstroms, such as Dowex MARATHON WBA (trademark of Dow Chemical).

A 0.5 to 20 times weight of aqueous solution of the 1,3-position specific type lipase with respect to the immobilizing support is suspended therein, and a 2 to 5 times amount of cold acetone (for example, -80°C) with respect to the suspension is slowly added while stirring to form a precipitate. The precipitate is dried under reduced pressure to prepare the immobilized enzyme. As a simpler method, a 0.05 to 0.4 times amount of the 1,3-position specific type lipase with respect to the



immobilizing support is dissolved in a minimal amount of water, and then the solution is mixed with the immobilizing support while stirring and the mixture is dried under reduced pressure to prepare the immobilized enzyme. This procedure results in immobilization of about 90% of the lipase on the support but with absolutely no exhibited transesterification activity, and therefore the immobilized enzyme may be activated and provided for production most efficiently by pretreatment in the substrate (raw material oil or fat and medium-chain fatty acids) containing 1 to 10 wt% (W/V) water, and preferably in the substrate containing 1 to 3 wt% water.

The amount of water added to the reaction system is extremely important depending on the type of enzyme, since transesterification will not proceed in the absence of water, while an excess of water causes hydrolysis and a reduced glyceride yield (with diglycerides and monoglycerides being produced upon hydrolysis). In such cases, however, the immobilized enzyme activated by pretreatment may be used to lessen the importance of the amount of water added to the reaction system, allowing transesterification reaction to occur efficiently even in a system containing no water. Moreover, the type of enzyme agent may also be selected to allow omission of pretreatment.

Thus, by using a heat-resistant immobilized enzyme and increasing the enzyme reaction temperature, it is possible to efficiently produce triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position without reduction in reaction efficiency, even in the case of arachidonic acid-containing oils or fats (triglycerides) with low reactivity for 1,3-position specific type lipases.

The process for production of foods and beverages with effects of decline prevention, improvement or

enhancement of normal responses of cognitive abilities of a healthy person employs arachidonic acid and/or a compound with arachidonic acid as a constituent fatty acid, either alone or in admixture with a food or beverage material containing essentially no, or only a trace amount of, arachidonic acid. Here, "trace amount" means that arachidonic acid is present in the food or beverage material but in an amount which does not reach the daily intake of arachidonic acid according to the invention, as described hereunder, if the food composition is ingested by an individual.

Oils and fats (triglycerides) containing arachidonic acid as part or all of the constituent fatty acid have unlimited possibilities for use as raw materials and additives in foods, beverages, pharmaceuticals and quasi drugs. Furthermore, there are no limitations on the purpose or amounts of their use.

As examples of food compositions there may be mentioned common food products as well as functional foods, nutritional supplements, modified milk for immature infants, modified milk for infants, infant food products, maternal foods or geriatric foods. As examples of food products containing oils or fats there may be mentioned natural foods which originally contain oils and fats, such as meat, fish and nuts, food products with oils and fats added during preparation, such as soups, food products using oils or fats as heating media, such as donuts, oil or fat food products such as butter, processed food products with oils or fats added during processing, such as cookies, or food products sprayed or coated with oils or fats during final processing, such as hard biscuits. They may also be added to agricultural foods, fermented foods, livestock foods, marine foods or beverages which contain no oils or fats. They may also be in the form of functional food products, pharmaceuticals or quasi drugs, and for example, in the form of enteral nutrients, powders, granules, lozenges,

oral solutions, suspensions, emulsions, syrups or the like.

The composition of the invention may also contain, in addition to the active ingredient of the invention, various carriers and additives commonly used in foods and beverages, pharmaceuticals or quasi drugs. In particular it preferably contains antioxidants in order to prevent oxidation of the active ingredient of the invention. As antioxidants there may be mentioned natural antioxidants such as tocopherols, flavone derivatives, phyllostulcin, kojic acid, gallic acid derivatives, catechins, fukiic acid, gossypol, pyrazine derivatives, sesamol, guaiaol, guaiac acid, p-coumaric acid, nordihydroguaiatic acid, sterols, terpenes, nucleic acid bases, carotenoids, lignans and the like, and synthetic antioxidants such as ascorbic palmitic ester, ascorbic stearic ester, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), mono-t-butylhydroquinone (TBHQ) and 4-hydroxymethyl-2,6-di-t-butylphenol (HMBP). As tocopherols there may be mentioned  $\alpha$ -tocopherol,  $\beta$ -tocopherol,  $\gamma$ -tocopherol,  $\delta$ -tocopherol,  $\epsilon$ -tocopherol,  $\xi$ -tocopherol,  $\eta$ -tocopherol and tocopherol esters (acetic acid tocopherol, etc.). As examples of carotenoids there may be mentioned  $\beta$ -carotene, cantaxanthin, astaxanthin and the like.

As supports to be used in the composition of the invention in addition to the active ingredient of the invention, there may be mentioned various types of carrier supports, extenders, diluents, fillers, dispersing agents, excipients, binder solvents (for example, water, ethanol or vegetable oils), solubilizing aids, buffers, dissolution accelerators, gelling agents, suspending agents, wheat flour, rice flour, starch, corn starch, polysaccharides, milk protein, collagen, rice oil, lecithin and the like. As examples of additives there may be mentioned vitamins, sweeteners, organic acids, coloring agents, flavorings, dehumidifying agents,

fibers, electrolytes, minerals, nutrients, antioxidants, preservatives, aromatic agents, humidifiers, natural edible extracts, vegetable extracts and the like, although there is no limitation to these.

5           The principal medicinal component of the arachidonic acid or the compound with arachidonic acid as a constituent fatty acid is arachidonic acid. The daily intake of arachidonic acid from food is reported to be 0.14 g in the Kanto region, Japan and 0.19-0.20 g in the  
10   Kansai region, Japan (see "Shishitsu Eiyogaku" [Lipid Nutrition] 4, ed. by the Japan Society for Lipid Nutrition Editing Committee, pp.73-82(1995) ISN 1343-4594 CODEN:SHEIFG), and therefore arachidonic acid must be ingested in a corresponding amount or greater. Thus, the  
15   daily intake of arachidonic acid or a compound with arachidonic acid as a constituent fatty acid according to the invention for an adult (60 kg body weight, for example) is 0.001-20 g, preferably 0.01-10 g, more preferably 0.05-5 g and most preferably 0.1-2 g, in terms  
20   of arachidonic acid.

          When the active ingredient of the invention is actually used in a food or beverage product, the absolute amount of arachidonic acid in the food product is also important. However, since the absolute amount in the  
25   food or beverage also varies depending on the amount of ingestion of the food or beverage, the food product preferably contains the triglycerides including triglycerides with arachidonic acid as part or all of the constituent fatty acid, in an amount of at least 0.0003  
30   wt%, preferably at least 0.003 wt% and more preferably at least 0.03 wt% in terms of arachidonic acid. When triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position are added to a food or beverage, the amount of  
35   the triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position is at least 0.001 wt%, preferably at least 0.01

wt% and more preferably at least 0.1 wt%.

When the composition of the invention is used as a pharmaceutical product, it may be produced by a common method for drug manufacturing, for example, a method described the Japanese Pharmacopoeia, or a method based thereon.

When the composition of the invention is used as a pharmaceutical product, the content of the active ingredient in the composition is not particularly restricted so long as the object of the invention is achieved, and the mixing proportion may be as deemed appropriate.

When the composition of the invention is used as a pharmaceutical product, it is preferably administered in unit dosages, with oral administration being particularly preferred. The doses of the composition of the invention will differ depending on the age, body weight and symptoms of the patient and the number of times administered, and for example, the arachidonic acid and/or compound with arachidonic acid as a constituent fatty acid according to the invention may usually be administered at about 0.001-20 g, preferably about 0.01-10 g, more preferably about 0.05-5 g and most preferably about 0.1-2 g in terms of arachidonic acid per day for an adult (approximately 60 kg), in divided doses of 1 to 3 times a day.

The major fatty acids of brain phospholipid membranes are arachidonic acid and docosahexaenoic acid, and therefore the composition of the invention is preferably a combination of arachidonic acid and docosahexaenoic acid in consideration of maintaining balance. Generally speaking, arachidonic acid (n-6 unsaturated fatty acid) and docosahexaenoic acid (n-3 unsaturated fatty acid) are biosynthesized by the same enzyme from linoleic acid and  $\alpha$ -linolenic acid, respectively. When arachidonic acid is administered alone, therefore, biosynthesis of docosahexaenoic acid is

inhibited. Conversely, when docosahexaenoic acid is administered alone, biosynthesis of arachidonic acid is inhibited. In order to avoid such unbalances, it is preferred for arachidonic acid and docosahexaenoic acid to be consumed in combination. Furthermore, as the proportion of eicosapentaenoic acid is very low in brain phospholipid membranes, the combination preferably contains virtually no eicosapentaenoic acid. It therefore preferably contains no eicosapentaenoic acid, or only up to 1%. The composition more preferably contains virtually no eicosapentaenoic acid with the arachidonic acid and docosahexaenoic acid. The combination of arachidonic acid and docosahexaenoic acid also preferably has an arachidonic acid/docosahexaenoic acid ratio (by weight) in the range of 0.1-15 and preferably in the range of 0.25-10. Most preferred are foods and beverages containing eicosapentaenoic acid at no more than 1/5 (by weight) of the arachidonic acid.

The food compositions of the invention for foods or beverages, healthy foods, functional foods, special health care foods, infant foods, geriatric foods and the like include those which are marketed using packaging containers and/or food composition merchandising tools (for example, pamphlets or the like) which state or otherwise indicate that the compositions and/or components in the composition have effects of decline prevention, improvement or enhancement of cognitive abilities, or stated differently, that they have effects of decline prevention, improvement or enhancement of normal responses of awareness level of a healthy person, effects of decline prevention, improvement or enhancement of normal responses of discriminatory ability of a healthy person with respect to events (auditory stimuli, visual stimuli, gustatory stimuli, olfactory stimuli, somatosensory stimuli) and effects of decline prevention, improvement or enhancement of normal functions such as attention, memory, perception, language, calculation and

the like, as well as having effects of maintaining or enhancing concentration, maintaining attention, clearing the head or stimulating the mind, rejuvenation and the like.

5

#### EXAMPLES

The present invention will now be explained in greater detail through the following examples, with the understanding that these examples in no way limit the invention.

10

#### Example 1

Production process for triglycerides with arachidonic acid as a constituent fatty acid

15        *Mortierella alpina* was used as an arachidonic acid-producing strain. A 6 kL portion of medium containing 1.8% glucose, 3.1% defatted soybean flour, 0.1% soybean oil, 0.3%  $\text{KH}_2\text{PO}_4$ , 0.1%  $\text{Na}_2\text{SO}_4$ , 0.05%  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  and 0.05%  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$  was prepared in a 10 kL culturing vessel, and  
20        the initial pH was adjusted to 6.0. After seeding 30 L of the culture solution, submerged culturing was conducted for 8 days under conditions of 26°C temperature, 360  $\text{m}^3/\text{h}$  aeration and 200 kPa interior pressure. The spinning was adjusted to maintain a  
25        dissolved oxygen concentration of 10-15 ppm. Also, the glucose concentration of the medium was adjusted by feeding to be in the range of 1-2.5% up to the 4th day, and 0.5-1% thereafter (where the percentages are based on weight (W/V)). After completion of the culturing,  
30        followed by filtering and drying, the cells containing triglycerides with arachidonic acid as a constituent fatty acid were collected, the oil/fat was obtained from the obtained cells by hexane extraction, and the edible oil/fat was subjected to a purification step (degumming,  
35        deacidification, steam distillation, decoloration) to obtain 150 kg of arachidonic acid-containing triglycerides (with arachidonic acid bound at any

positions of the triglycerides). The obtained oil/fat (triglyceride) was methylesterified and the resulting fatty acid methyl ester was analyzed by gas chromatography, which revealed an arachidonic acid proportion of 40.84% of the total fatty acids. The palmitic acid, stearic acid, oleic acid, linoleic acid,  $\gamma$ -linolenic acid and dihomo- $\gamma$ -linolenic acid contents were 11.63%, 7.45%, 7.73%, 9.14%, 2.23% and 3.27%, respectively. The arachidonic acid-containing oil/fat (triglyceride) was ethylesterified and 99% arachidonic acid ethyl ester was separated and purified from the fatty acid ethyl ester mixture comprising 40% arachidonic acid ethyl ester, by ordinary high performance liquid chromatography.

15

#### Example 2

Production of triglycerides including at least 5% of triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position (8A8)

20

After suspending 100 g of an ion-exchange resin support (Dowex MARATHON WBA™: Dow Chemical) in 80 ml of 12.5% aqueous *Rhizopus delemar* lipase solution (Talipase powder, product of Tanabe Seiyaku), the suspension was dried under reduced pressure to obtain the immobilized lipase.

25

Next, 80 g of the triglyceride containing 40 wt% arachidonic acid obtained in Example 1 (TGA40S), 160 g of caprylic acid, 12 g of the aforementioned immobilized lipase and 4.8 ml of water were reacted at 30°C for 48 hours while stirring (130 rpm). After completion of the reaction, the reaction mixture was removed to obtain the activated immobilized lipase.

30

A 10 g portion of the immobilized enzyme (*Rhizopus delemar* lipase, support: Dowex MARATHON WBA™) was packed into a jacketed glass column (1.8 x 12.5 cm, 31.8 ml

35



volume), and a mixed oil containing the TGA40S obtained in Example 1 and caprylic acid in a proportion of 1:2 was passed through the column at a fixed flow rate (4 ml/h) for continuous reaction to obtain 400 g of reacted oil/fat. The column temperature was 40-41°C. The unreacted caprylic acid and free fatty acids were removed from the reacted oil/fat by molecular distillation, and the edible oil/fat was subjected to a purification step (degumming, deacidification, steam distillation, decoloration) to obtain 8A8-containing oil/fat (triglycerides). The 8A8 content of the obtained 8A8-containing oil/fat (triglycerides) was 31.6% as determined by gas chromatography and high performance liquid chromatography. (The proportions of 8P8, 8O8, 8L8, 8G8 and 8D8 were 0.6, 7.9, 15.1, 5.2 and 4.8%, respectively. The fatty acids P, O, L, G and D bound at the triglyceride 2-position represent palmitic acid, oleic acid, linoleic acid,  $\gamma$ -linolenic acid and dihomogamma-linolenic acid, respectively, 8P8 is 1,3-capryloyl-2-palmitoleyl-glycerol, 8O8 is 1,3-capryloyl-2-oleoyl-glycerol, 8L8 is 1,3-capryloyl-2-linoleoyl-glycerol, 8G8 is 1,3-capryloyl-2- $\gamma$ -linolenoyl-glycerol and 8D8 is 1,3-capryloyl-2-dihomo- $\gamma$ -linolenoyl-glycerol.) Separation and purification by high performance liquid chromatography according to an established protocol yielded 96 mole percent 8A8 from the obtained 8A8-containing oil/fat (triglycerides).

### Example 3

#### 30 Production of test capsules

Water was added to 100 parts by weight of gelatin and 35 parts by weight of food grade glycerin for dissolution at 50-60°C to prepare a gelatin coating with a viscosity of 2000 cp. Next, 0.05 wt% vitamin E oil was mixed with the arachidonic acid-containing oil/fat (triglycerides) obtained in Example 1 to prepare Filling

Content 1. Separately, 0.05 wt% vitamin E oil was mixed with oil/fat (triglycerides) containing 32 mole percent of the 8A8 obtained in Example 2 to prepare Filling

Content 2. Filling Content 1 was used for molding and drying of capsules by a common method to manufacture soft capsules containing 200 mg of filling per capsule (arachidonic acid-containing edible oil capsules) while Filling Content 2 was also used for molding and drying of capsules by a common method to manufacture soft capsules containing 200 mg of filling per capsule (8A8-containing edible oil capsules). Soft capsules containing olive oil as the filling content were also manufactured as placebo capsules for a human test.

#### Example 4

Arachidonic acid-containing edible oil capsule ingestion test to determine effects on cognitive responses in healthy individuals

The event related potentials of brain (ERP) was measured by audible (or auditory discrimination) tasks according to the evoked potential measuring guidelines established by the Evoked Potential Examination Standards Committee of the Japan Society of Clinical Neurophysiology. Specifically, an auditory oddball paradigm was utilized for the ERP measurement and both ears of the test subject were stimulated by two different pure tones at frequencies of 1000 Hz and 2000 Hz were through headphones at ratio of 1:4 and in random order, and the subject was instructed to press a provided button when the 2000 Hz tone was heard and to count the number of times heard. The intensity of the tone was 90 dB, the duration was 100 msec and the inter stimulus interval was random between 1000-3000 msec. The approximate number of stimulations in the actual test was 200 per trial and the duration of the test was about 10 minutes. The test was conducted in 2 trials and the event related potentialss of brain were measured. Electroencephalographies (EEGs)

were recorded by using Ag-AgCl electrodes, of which resistance is no greater than 5 k $\Omega$ , placed at three points along the mid-line of the scalp (Fz, Cz and Pz, according as international 10-20 displacements), and  
5 reference electrodes on both earlobes.

The maximum positive potential between 250-600 msec from the start of the low-frequency auditory simulation to be perceived (a 2000 Hz tone in this experiment) was identified as the intrinsic component P300 which varies  
10 in evaluation of selective attention or cognitive response, the time from the start of stimulation was recorded as the P300 latency (stimulation transmission speed) and the height of the potential from the baseline was recorded as the P300 amplitude (the amount of  
15 information processing resources).

The human test for the invention was conducted with due consideration to adhering to the spirit of the Helsinki Declaration.

Upon explanation for consent to test participation,  
20 12 consenting healthy individuals (taking no medication, with no abnormal blood test results and with no infarctions as determined by cranial CT scan) were divided into two groups A and B (A: n=7, B: n=5). During a one month period, Group A was administered three of the  
25 arachidonic acid-containing edible oil capsules prepared in Example 3 (80 mg/capsule arachidonic acid) for a daily arachidonic acid intake of 240 mg, while Group B was administered three placebo capsules. The event related potentialss of brain were measured before and after  
30 capsule ingestion, and the P300 latency and amplitude were analyzed. The participants in Groups A and B were then taken off the capsules for a washout period of one month. After the washout period, Group A was  
35 administered the placebo capsules and Group B was administered the arachidonic acid-containing edible oil capsules for one month, and the event related potentialss of brain were measured in the same manner before and

after capsule ingestion (double blind, crossover test).

Blood was taken at the time of event related potentials of brain measurement, and the total lipids were extracted from the serum of each participant by the Folch method. The lipids were fractionated by thin-layer chromatography, the phospholipid fraction was collected, the water was removed by azeotropic distillation with ethanol, and analysis was performed by gas chromatography upon conversion to fatty acid methyl ester with 10% HCl-methanol, to determine the arachidonic acid content of the serum phospholipids.

Fig. 1 shows changes in arachidonic acid contents in serum phospholipids before and after capsule ingestion. The arachidonic acid contents of the serum phospholipids of subjects ingesting the arachidonic acid-containing edible oil capsules were significantly increased after ingestion of the arachidonic acid-containing edible oil capsules, whereas the arachidonic acid contents of the serum phospholipids of subjects ingesting the placebo capsules were unchanged before and after ingestion of the placebo capsules.

Fig. 2 and Fig. 3 show changes in P300 latency and amplitude before and after capsule ingestion. The P300 latency was significantly shortened by 12.3 msec and the P300 amplitude was significantly increased by 1.9  $\mu$ V with ingestion of the arachidonic acid-containing edible oil capsules as compared to the placebo capsules. A normal shortening in P300 latency of 1.8 msec/year and decrease in P300 amplitude of 0.2  $\mu$ V/year are known (Goodin DS et al. 1978), and therefore the results of this test indicate an average rejuvenation for cognitive responses of the subjects of 6.8 years based on P300 latency and 9.5 years based on P300 amplitude.

Next, the correlation between P300 (P300 latency and P300 amplitude) and serum arachidonic acid level (phospholipid) was determined by a first-order curve

based on the least square method using total of 48 data obtained by measuring each of 12 subjects 4 times (Fig. 4). For P300 latency, a significant correlation (coefficient of correlation  $R = -0.27$ ) was found between the arachidonic acid levels, with shorter latencies resulting from increased arachidonic acid levels. For P300 amplitude as well, a significant correlation (coefficient of correlation  $R = -0.49$ ) was found between the arachidonic acid levels, with larger P300 amplitudes resulting from increased arachidonic acid levels. This constitutes the first demonstration of improvement of cognitive response by ingestion of arachidonic acid-containing edible oil, and the first proof of arachidonic acid as the cause of the effect.

15

#### Example 5

8A8-containing edible oil capsule ingestion test to determine effects on cognitive responses in healthy individuals

20 Upon explanation for consent to test participation in the same manner as Example 4, 16 consenting healthy individuals (taking no medication, with no abnormal blood test results and with no infarctions as determined by cranial CT scan) were divided into two groups A and B (n=8 for each group). During a one month period, Group A was administered three of the 8A8-containing edible oil capsules prepared in Example 3 (72 mg/capsule arachidonic acid) while Group B was administered three placebo capsules, and upon measuring the event related potentialss of brain and recording the latency and amplitude before and after capsule ingestion (double-blind test), the P300 latency was found to be significantly shortened by 16.3 msec and the P300 amplitude significantly increased by 2.4  $\mu V$  due to ingestion of the 8A8-containing edible oil capsules. These results indicate an average rejuvenation for cognitive responses of the subjects of 9.1 years based on

P300 latency and 12.0 years based on P300 amplitude.

#### Example 6

Preparation of capsules containing oil/fat

5 (triglycerides) with arachidonic acid as a constituent fatty acid

Water was added to 100 parts by weight of gelatin and 35 parts by weight of food grade glycerin for dissolution at 50-60°C to prepare a gelatin coating with a viscosity of 2000 cp. Next, 50 wt% of the arachidonic acid-containing oil/fat (triglycerides) obtained in Example 1 was mixed with 50 wt% fish oil (tuna oil comprising eicosapentaenoic acid and docosahexaenoic acid in proportions of 5.1% and 26.5%, respectively, of the total fatty acids), and this was combined with 0.05 wt% vitamin E oil to prepare Filling Content 3. Separately, 80 wt% of the arachidonic acid-containing oil/fat (triglycerides) was mixed with 20 wt% fish oil (tuna oil comprising eicosapentaenoic acid and docosahexaenoic acid in proportions of 5.1% and 26.5%, respectively, of the total fatty acids), and this was combined with 0.05 wt% vitamin E oil to prepare Filling Content 4. The 99% arachidonic acid ethyl ester obtained in Example 1 was also combined with 0.05 wt% vitamin E oil to obtain Filling Content 5. Filling Contents 3-5 were used for molding and drying of capsules by a common method to manufacture soft capsules containing 200 mg of filling per capsule.

#### 30 Example 7

Use in oil infusion solutions

After combining 400 g of the oil/fat (triglycerides) containing 96% 8A8 obtained in Example 2, 48 g of purified egg yolk lecithin, 20 g of oleic acid, 100 g of glycerin and 40 ml of 0.1 N caustic soda and dispersing the mixture with a homogenizer, distilled water for injection was added to 4 liters. This was emulsified

with a high-pressure spray-type emulsifier to prepare a lipid emulsion. The lipid emulsion was dispensed into plastic bags in portions of 200 ml and subjected to high-pressure steam sterilization treatment at 121°C for 20 minutes to prepare oil infusion solutions.

#### Example 8 Use in juice

A 2 g portion of  $\beta$ -cyclodextrin was added to 20 ml of a 20% aqueous ethanol solution, and then 100 mg of the arachidonic acid-containing triglycerides obtained in Example 1 (comprising 0.05% vitamin E) was added thereto while stirring with a stirrer, and the mixture was incubated at 50°C for 2 hours. After cooling to room temperature (approximately 1 hour), incubation was continued at 4°C for 10 hours under continuous stirring. The produced precipitate was recovered by centrifugal separation, and after washing with n-hexane, it was lyophilized to obtain 1.8 g of a cyclodextrin clathrated compound containing arachidonic acid-containing triglycerides. A 1 g portion of this powder was uniformly mixed with 10 L of juice to prepare juice containing arachidonic acid-containing triglycerides.

CLAIMS

1. A composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person,  
5 containing arachidonic acid and/or a compound with arachidonic acid as a constituent fatty acid.

2. A composition according to claim 1, wherein the compound with arachidonic acid as a constituent fatty acid is an arachidonic acid alcohol ester or a  
10 triglyceride, phospholipid or glycolipid containing arachidonic acid as part or all of the constituent fatty acid.

3. A composition according to claim 2, wherein the triglyceride containing arachidonic acid as part or all  
15 of the constituent fatty acid is a triglyceride having medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position.

4. A composition according to claim 3, wherein the medium-chain fatty acids are selected from among fatty  
20 acids of 6 to 12 carbons.

5. A composition according to claim 4, wherein the medium-chain fatty acids are selected from among fatty acids of 8 carbons.

6. A composition with effects of decline  
25 prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, which contains triglycerides including triglycerides containing arachidonic acid as part or all of the constituent fatty acid.

7. A composition according to claim 6,  
30 characterized in that the arachidonic acid content of the triglycerides including triglycerides containing arachidonic acid as part or all of the constituent fatty acid is at least 10 wt% of the total fatty acid in the  
35 triglycerides.

8. A composition according to claim 6 or 7, wherein the triglycerides including triglycerides



containing arachidonic acid as part or all of the constituent fatty acid are extracted from microbes belonging to the genus *Mortierella*.

5           9. A composition according to any one of claims 6 to 8, wherein the triglycerides including triglycerides containing arachidonic acid as part or all of the constituent fatty acid are triglycerides containing no eicosapentaenoic acid or containing no more than 1% eicosapentaenoic acid.

10           10. A composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, which contains triglycerides including at least 5 mole percent of triglycerides with medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at  
15           the 2-position.

          11. A composition according to claim 10, wherein the medium-chain fatty acids are selected from among fatty acids of 6 to 12 carbons.

20           12. A composition according to claim 11, wherein the medium-chain fatty acids are selected from among fatty acids of 8 carbons.

          13. A composition according to any one of claims 1 to 12 with effects of decline prevention, improvement or  
25           enhancement of the normal responses of a healthy person of processing speed or response speed with respect to events selected from the group consisting of auditory stimuli, visual stimuli, olfactory stimuli, gustatory stimuli and somatosensory stimuli, as a cognitive  
30           ability.

          14. A composition according to any one of claims 1 to 12 with effects of decline prevention, improvement or enhancement of the normal response of concentration of a healthy person with respect to events selected from the  
35           group consisting of auditory stimuli, visual stimuli, olfactory stimuli, gustatory stimuli and somatosensory stimuli, as a cognitive ability.

15. A composition according to any one of claims 1 to 12 with effects of decline prevention, improvement or enhancement of the normal response of awareness level of a healthy person, as a cognitive ability.

5 16. A composition according to any one of claims 1 to 12 with effects of decline prevention, improvement or enhancement of the normal response of discriminatory ability of a healthy person with respect to events  
10 selected from the group consisting of auditory stimuli, visual stimuli, olfactory stimuli, gustatory stimuli and somatosensory stimuli, as a cognitive ability.

17. A composition according to any one of claims 1 to 12 with an effect of shortening P300 latency of the event related potentials of brain (P300), as a response  
15 index of cognitive ability.

18. A composition according to any one of claims 1 to 12 with an effect of augmenting the P300 amplitude of the event related potentials of brain (P300), as a response index of cognitive ability.

20 19. A composition according to any one of claims 1 to 18, wherein the composition is a food composition or pharmaceutical composition.

20. A food composition containing arachidonic acid and/or a compound with arachidonic acid as a constituent  
25 fatty acid, in an amount such that the daily ingestion for an adult is 0.001-20 g in terms of arachidonic acid.

21. A food composition according to claim 20, wherein the compound with arachidonic acid as a constituent fatty acid is an arachidonic acid alcohol  
30 ester or a triglyceride, phospholipid or glycolipid comprising arachidonic acid as part or all of the constituent fatty acid.

22. A food composition according to claim 21, wherein the triglyceride containing arachidonic acid as  
35 part or all of the constituent fatty acid is a triglyceride having medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-

position.

23. A food composition according to claim 22, wherein the medium-chain fatty acids are selected from among fatty acids of 6 to 12 carbons.

5           24. A food composition according to claim 23, wherein the medium-chain fatty acids are selected from among fatty acids of 8 carbons.

25. A food composition characterized in that the composition contains at least 0.001 wt% of triglycerides  
10           having medium-chain fatty acids bound at the 1,3-positions and arachidonic acid bound at the 2-position.

26. A food composition according to claim 25, wherein the medium-chain fatty acids are selected from among fatty acids of 6 to 12 carbons.

15           27. A food composition according to claim 26, wherein the medium-chain fatty acids are selected from among fatty acids of 8 carbons.

28. A composition according to any one of claims 20 to 27, wherein the food composition is a functional food, nutritional supplement food, special health care food or  
20           geriatric food.

29. A composition according to any one of claims 1 to 28, which further comprises docosahexaenoic acid and/or a compound with docosahexaenoic acid as a  
25           constituent fatty acid.

30. A composition according to claim 29, wherein the compound with docosahexaenoic acid as a constituent fatty acid is a docosahexaenoic acid alcohol ester or a triglyceride, phospholipid or glycolipid comprising  
30           docosahexaenoic acid as part or all of the constituent fatty acid.

31. A composition according to claim 29 or 30, characterized in that the arachidonic acid/docosahexaenoic acid ratio (by weight) in a  
35           combination of the arachidonic acid and docosahexaenoic acid is in the range of 0.1-15.

32. A composition according to any one of claims 1

to 31, characterized in that eicosapentaenoic acid is also present in the composition in an amount not exceeding 1/5 of the arachidonic acid in the composition.


33. A process for production of a food composition  
5 with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, characterized by combining arachidonic acid and/or a compound with arachidonic acid as a constituent fatty acid, either alone or with a food  
10 material containing either essentially no or only a trace amount of arachidonic acid.

34. A method for marketing a composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy  
15 person containing arachidonic acid and/or a compound with arachidonic acid as a constituent fatty acid, the method for marketing a composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person  
20 being characterized by using a packaging container and/or merchandising tool which indicates that the composition and/or components in the composition have effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person.

25 35. A composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person, characterized by being a composition containing arachidonic acid and/or a compound with arachidonic acid  
30 as a constituent fatty acid which is marketed using a packaging container and/or merchandising tool for the composition indicating that the composition and/or components in the composition have effects of decline prevention, improvement or enhancement of normal  
35 responses of cognitive abilities of a healthy person.

1/4


Fig. 1



(N=12, paired t-test)

2/4


Fig.2



3/4


Fig.3

◆- ARACHIDONIC ACID-CONTAINING EDIBLE OIL CAPSULES  
□- OLIVE OIL-CONTAINING CAPSULES (DUMMY CAPSULES)



↑  
INCREASING P300  
AMPLITUDE

Fig.4





A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/202 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, PAJ, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 080 787 A (DOHNALEK MARGARET H ET AL) 27 June 2000 (2000-06-27)	1,2,6, 13-21, 29-35
Y	column 13, line 39-48; claims 1-7,16,17,25	1-35
X	WO 96 10922 A (MILUPA AG ;KOHN GERHARD (DE); SAWATZKI GUENTHER (DE); SCHWEIKHARDT) 18 April 1996 (1996-04-18)	1,2,6, 13-21, 29-35
Y	page 4, line 5 -page 5, line 34; claims 1-4	1-35
X	US 6 034 130 A (BERTHOLET RAYMOND ET AL) 7 March 2000 (2000-03-07)	1-7,9-35
Y	column 2, line 18-61; claims 1,8; example 1; table 3	1-35
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

22 January 2004

Date of mailing of the international search report

03/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Greif, G

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 239 022 A (NESTLE SA) 11 September 2002 (2002-09-11) claims 1-3,10-14 ----	1,2,6, 33-35
X	WO 96 21037 A (MARTEK BIOSCIENCES CORP ;KYLE DAVID J (US)) 11 July 1996 (1996-07-11) page 4, line 1 -page 5, line 14; claims 1-34 ----	1,2,6-9, 13-21, 33-35 1-35
Y	US 4 668 704 A (TARNAWSKI ANDRZEJ S ET AL) 26 May 1987 (1987-05-26) column 2, line 6-52 ----	1,6, 33-35
X	KOLETZKO B ET AL: "Polyunsaturated fatty acids in human milk and their role in early infant development." JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. UNITED STATES JUL 1999, vol. 4, no. 3, July 1999 (1999-07), pages 269-284, XP009024376 ISSN: 1083-3021 page 270, right-hand column, paragraph 1; table 1 ----	1-3,6,7, 10, 13-22, 25,29, 30,33-35
Y	CARLSON S E: "Docosahexaenoic acid and arachidonic acid in infant development." SEMINARS IN NEONATOLOGY: SN. ENGLAND OCT 2001, vol. 6, no. 5, October 2001 (2001-10), pages 437-449, XP008024374 ISSN: 1084-2756 abstract p. 438, "Effects of essential fatty acid deficiency on brain composition and function" ----	1-35
Y	AUESTAD NANCY ET AL: "Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age." PEDIATRICS. UNITED STATES SEP 2003, vol. 112, no. 3 Pt 1, September 2003 (2003-09), pages e177-e183, XP009024347 ISSN: 1098-4275 abstract ----- -/--	1-35

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WILLATTS P ET AL: "Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age"</p> <p>LANCET, XX, XX, vol. 352, no. 9129, 29 August 1998 (1998-08-29), pages 688-691, XP004265590 ISSN: 0140-6736 page 690, right-hand column, line 1-7; table 1</p>	1-35
Y	<p>-----</p> <p>LUCAS A A ET AL: "Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomised trial"</p> <p>LANCET, XX, XX, vol. 354, no. 9194, 4 December 1999 (1999-12-04), pages 1948-1954, XP004262925 ISSN: 0140-6736 page 1948, right-hand column, paragraphs 1,2</p> <p>-----</p>	1-35

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6080787	A	27-06-2000	AU 732903 B2	03-05-2001
			AU 6176998 A	09-09-1998
			BR 9807443 A	25-04-2000
			CN 1269718 T	11-10-2000
			EP 1039892 A2	04-10-2000
			HU 0300236 A2	28-06-2003
			ID 22744 A	09-12-1999
			IL 131126 A	10-04-2003
			JP 2001516343 T	25-09-2001
			NO 994052 A	20-10-1999
			NZ 337039 A	29-06-2001
			PL 343902 A1	10-09-2001
			RU 2199317 C2	27-02-2003
			SK 112399 A3	11-12-2000
			TR 9902023 T2	21-09-2001
			WO 9836745 A2	27-08-1998
			US 6306908 B1	23-10-2001
			US 6036992 A	14-03-2000
WO 9610922	A	18-04-1996	AT 167983 T	15-07-1998
			CA 2201931 A1	18-04-1996
			DE 59502779 D1	13-08-1998
			DK 784437 T3	19-04-1999
			WO 9610922 A1	18-04-1996
			EP 0784437 A1	23-07-1997
			ES 2118629 T3	16-09-1998
			JP 10508193 T	18-08-1998
US 6034130	A	07-03-2000	EP 0893064 A1	27-01-1999
			AT 230935 T	15-02-2003
			AU 732818 B2	03-05-2001
			AU 7732398 A	04-02-1999
			BR 9802541 A	20-07-1999
			CA 2239806 A1	22-01-1999
			CN 1205839 A	27-01-1999
			DE 69718455 D1	20-02-2003
			DE 69718455 T2	30-04-2003
			DK 893064 T3	22-04-2003
			ES 2188855 T3	01-07-2003
			IL 124947 A	28-01-2001
			JP 11089513 A	06-04-1999
			NO 983212 A	25-01-1999
			NZ 330892 A	30-08-1999
			PL 327597 A1	01-02-1999
			PT 893064 T	30-04-2003
			RU 2205546 C2	10-06-2003
			TR 9801413 A1	22-02-1999
			TW 387797 B	21-04-2000
			US 6297279 B1	02-10-2001
			ZA 9806496 A	21-01-2000
EP 1239022	A	11-09-2002	EP 1239022 A1	11-09-2002
			CA 2438601 A1	19-09-2002
			WO 02072742 A1	19-09-2002
			NO 20033894 A	03-09-2003
WO 9621037	A	11-07-1996	US 5658767 A	19-08-1997
			AT 239088 T	15-05-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9621037	A		AU 713567 B2	02-12-1999
			AU 4854296 A	24-07-1996
			BR 9607179 A	11-11-1997
			CA 2209513 A1	11-07-1996
			CN 1175976 A	11-03-1998
			DE 69627816 D1	05-06-2003
			DE 69627816 T2	22-01-2004
			DE 800584 T1	06-05-1999
			DK 800584 T3	04-08-2003
			EA 1036 B1	28-08-2000
			EP 1342787 A2	10-09-2003
			EP 0800584 A1	15-10-1997
			FI 972829 A	02-09-1997
			JP 10512444 T	02-12-1998
			NO 973085 A	03-09-1997
			PL 321208 A1	24-11-1997
			PT 800584 T	30-09-2003
			WO 9621037 A1	11-07-1996
US 4668704	A	26-05-1987	AT 41866 T	15-04-1989
			AU 559715 B2	19-03-1987
			AU 1758983 A	16-02-1984
			CA 1218308 A1	24-02-1987
			DE 3379533 D1	11-05-1989
			EP 0101294 A2	22-02-1984
			IE 55599 B1	21-11-1990
			IL 69439 A	31-08-1986
			JP 59062522 A	10-04-1984
			NZ 205076 A	30-04-1985
			PH 18285 A	20-05-1985
			US 4670468 A	02-06-1987
			ZA 8305830 A	30-05-1984